MicroRNA (miRNA) Market- Global Industry Analysis and Forecast (2021-2027) – by Research Tools, Application, End-use, and Region.

MicroRNA (miRNA) Market is expected to reach US$ 520 Mn. at a CAGR of 11.6 during the forecast period 2027. Global MicroRNA (miRNA) Market To know about the Research Methodology :- Request Free Sample Report The report has analyzed the revenue impact of the COVID-19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis. MicroRNA, also recognized as miRNA. It is a class of RNA that plays a vital role in the regulation of gene expression and is also involved in RNA silencing. MicroRNA is found in animals, plants, and some viruses. Generally, the development of well-organized and advanced technology, rise in consciousness, increasing focus on R&D, growing government initiative across the globe, development of molecular biology and genomic technologies, and growing government’s funding on healthcare are the major growth drivers of the global micro-RNA market. Growing number of patients suffering from cancer and other cardiovascular disorders, rising number of therapeutic applications, increasing adoption of the technology for use, reducing the cost of the sequencing are some of the factors which are driving the growth of the MicroRNA (miRNA) market in oncology in the forecast period (2019-2027). As well as, an increase in the adoption of micro-RNA in developing economies like China, India, and others, will create new opportunities for the global micro-RNA market. The high cost of kits and products with a lack of enhanced infrastructure are the restraints for the market growth of the MicroRNA (miRNA) market in oncology in the forecast period. The growing demand for skilled personnel along with challenges concerning in-house development of analysis which is the key challenge for the growth of the micro-RNA market. Existence of several companies, particularly domestic players creating massive price competition. Thermo Fisher Scientific Inc. is the leader in the global microRNA market in terms of revenue share in 2018, because of a varied product portfolio. Thermo Fisher Scientific Inc. also offers microRNA products exactly catering to the animal health and agriculture segment. Hence its wide product range providing to different end-users make it a market leader in the microRNA market. Illumina Inc., takings second position in the global microRNA market. The company has microarray kits and library preparation kits for miRNA. By End-use, Academic & government research institutes held the largest market share in the global market in 2018. This is mainly because of the rapid adoption of microRNA research tools by universities and research labs. The biotech & pharma companies segment is poised to post the highest CAGR in the forecast period, on account of the rapid adoption of research tools in the translation of scientific knowledge to clinical application. By region, North America held the largest market share of the global market in 2019, with approximately half of the world’s procedures being done in the U.S. because of high medical reimbursement facilities, support from the government, and technological advancement. Asia Pacific micro-RNA market is expected to grow with a significant pace, because of the fast increasing population, rise in consumer awareness, favorable government policies, modernization of healthcare infrastructure, and upward investments by the foreign countries in emerging countries such as China, and India in the APAC region. As well as, remarkable progress in genomic studies and the rising adoption of innovative technologies are expected to encourage the growth of the Asia Pacific market. For example, TaKaRa Bio, are involved in the development of products that consist of arrays and kits, so improving the growth of the APAC region. The objective of the report is to present a comprehensive analysis of the Global MicroRNA (miRNA) Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global MicroRNA (miRNA) Market dynamics, structure by analyzing the market segments and project the Global MicroRNA (miRNA) Market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the Global MicroRNA (miRNA) Market make the report investor’s guide.

Scope of the Global MicroRNA (miRNA) Market: Inquire before buying

Global MicroRNA (miRNA) Market
Report Coverage Details
Base Year: 2020 Forecast Period: 2021-2027
Historical Data: 2016 to 2020 Market Size in 2020: US $ 241.19Bn.
Forecast Period 2021 to 2027 CAGR: 11.6% Market Size in 2027: US $ 520 Bn.
Segments Covered: by Research Tools • Services • Products
by Application • Cancer • Infectious Diseases • Immunological Disorder • Cardiovascular Disease • Neurological Disease • Others
by End-use • Biotechnology and Pharmaceutical Companies • Academic & Government Research Institutes • Others

Global MicroRNA (miRNA) Market, By Region

• North America • Europe • Asia Pacific • Middle East & Africa • South America

Key players operating in the Global MicroRNA (miRNA) Market

• Illumina, Inc. • F. Hoffmann-La Roche Ltd • Agilent Technologies • Bio-Rad Laboratories Inc. • Sigma Aldrich Corp. • Qiagen N.V • Thermo Fisher Scientific, Inc. • HTG Molecular Diagnostics, Inc. • Bioline GmbH (A Meridian Life Science Company) • Rosetta Genomics Ltd. • Dharmacon, a Horizon Discovery Group Co. • BioVendor — Laboratorní medicína a.s. • Miltenyi Biotec • Kaneka Corporation (Eurogentec) • Abcam Plc • GeneCopoeia, Inc. • Promega Corporation • New England Biolabs, Inc. • NanoString Technologies, Inc. • System Biosciences LLC • Others
Global MicroRNA (miRNA) Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Forms 2.3.2. Primary Research 2.3.2.1. Data from Primary Forms 2.3.2.2. Breakdown of Primary Forms 3. Executive Summary: Global MicroRNA (miRNA) Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global MicroRNA (miRNA) Market Analysis and Forecast 6.1. MicroRNA (miRNA) Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global MicroRNA (miRNA) Market Analysis and Forecast, By Research Tools 7.1. Introduction and Definition 7.2. Key Findings 7.3. MicroRNA (miRNA) Market Value Share Analysis, By Research Tools 7.4. MicroRNA (miRNA) Market Size (US$ Mn) Forecast, By Research Tools 7.5. MicroRNA (miRNA) Market Analysis, By Research Tools 7.6. MicroRNA (miRNA) Market Attractiveness Analysis, By Research Tools 8. Global MicroRNA (miRNA) Market Analysis and Forecast, By End-use 8.1. Introduction and Definition 8.2. Key Findings 8.3. MicroRNA (miRNA) Market Value Share Analysis, By End-use 8.4. MicroRNA (miRNA) Market Size (US$ Mn) Forecast, By End-use 8.5. MicroRNA (miRNA) Market Analysis, By End-use 8.6. MicroRNA (miRNA) Market Attractiveness Analysis, By End-use 9. Global MicroRNA (miRNA) Market Analysis and Forecast, By Application 9.1. Introduction and Definition 9.2. Key Findings 9.3. MicroRNA (miRNA) Market Value Share Analysis, By Application 9.4. MicroRNA (miRNA) Market Size (US$ Mn) Forecast, By Application 9.5. MicroRNA (miRNA) Market Analysis, By Application 9.6. MicroRNA (miRNA) Market Attractiveness Analysis, By Application 10. Global MicroRNA (miRNA) Market Analysis, by Region 10.1. MicroRNA (miRNA) Market Value Share Analysis, by Region 10.2. MicroRNA (miRNA) Market Size (US$ Mn) Forecast, by Region 10.3. MicroRNA (miRNA) Market Attractiveness Analysis, by Region 11. North America MicroRNA (miRNA) Market Analysis 11.1. Key Findings 11.2. North America MicroRNA (miRNA) Market Overview 11.3. North America MicroRNA (miRNA) Market Value Share Analysis, By Research Tools 11.4. North America MicroRNA (miRNA) Market Forecast, By Research Tools 11.4.1. Services 11.4.1.1. Sample collection 11.4.1.1.1. Whole Blood 11.4.1.1.2. Serum 11.4.1.1.3. Plasma 11.4.1.2. miRNA cDNA Synthesis 11.4.1.3. Profiling & Purification 11.4.1.4. Detection 11.4.1.5. Functional Studies 11.4.1.5.1. NGS 11.4.1.5.2. Microarray 11.4.1.5.3. Real Time PCR 11.4.1.5.4. Others 11.4.2. Products 11.4.2.1. Instruments 11.4.2.2. Consumables 11.4.2.3. Isolation & Purification 11.4.2.4. Quantification & Detection 11.4.2.5. Functional Analysis 11.4.2.6. Others 11.5. North America MicroRNA (miRNA) Market Value Share Analysis, By End-use 11.6. North America MicroRNA (miRNA) Market Forecast, By End-use 11.6.1. Biotechnology and Pharmaceutical Companies 11.6.2. Academic & Government Research Institutes 11.6.3. Others 11.7. North America MicroRNA (miRNA) Market Value Share Analysis, By Application 11.8. North America MicroRNA (miRNA) Market Forecast, By Application 11.8.1. Cancer 11.8.2. Infectious Diseases 11.8.3. Immunological Disorder 11.8.4. Cardiovascular Disease 11.8.5. Neurological Disease 11.8.6. Others 11.9. North America MicroRNA (miRNA) Market Value Share Analysis, by Country 11.10. North America MicroRNA (miRNA) Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America MicroRNA (miRNA) Market Analysis, by Country 11.12. U.S. MicroRNA (miRNA) Market Forecast, By Research Tools 11.12.1. Services 11.12.1.1. Sample collection 11.12.1.1.1. Whole Blood 11.12.1.1.2. Serum 11.12.1.1.3. Plasma 11.12.1.2. miRNA cDNA Synthesis 11.12.1.3. Profiling & Purification 11.12.1.4. Detection 11.12.1.5. Functional Studies 11.12.1.5.1. NGS 11.12.1.5.2. Microarray 11.12.1.5.3. Real Time PCR 11.12.1.5.4. Others 11.12.2. Products 11.12.2.1. Instruments 11.12.2.2. Consumables 11.12.2.3. Isolation & Purification 11.12.2.4. Quantification & Detection 11.12.2.5. Functional Analysis 11.12.2.6. Others 11.13. U.S. MicroRNA (miRNA) Market Forecast, By End-use 11.13.1. Biotechnology and Pharmaceutical Companies 11.13.2. Academic & Government Research Institutes 11.13.3. Others 11.14. U.S. MicroRNA (miRNA) Market Forecast, By Application 11.14.1. Cancer 11.14.2. Infectious Diseases 11.14.3. Immunological Disorder 11.14.4. Cardiovascular Disease 11.14.5. Neurological Disease 11.14.6. Others 11.15. Canada MicroRNA (miRNA) Market Forecast, By Research Tools 11.15.1. Services 11.15.1.1. Sample collection 11.15.1.1.1. Whole Blood 11.15.1.1.2. Serum 11.15.1.1.3. Plasma 11.15.1.2. miRNA cDNA Synthesis 11.15.1.3. Profiling & Purification 11.15.1.4. Detection 11.15.1.5. Functional Studies 11.15.1.5.1. NGS 11.15.1.5.2. Microarray 11.15.1.5.3. Real Time PCR 11.15.1.5.4. Others 11.15.2. Products 11.15.2.1. Instruments 11.15.2.2. Consumables 11.15.2.3. Isolation & Purification 11.15.2.4. Quantification & Detection 11.15.2.5. Functional Analysis 11.15.2.6. Others 11.16. Canada MicroRNA (miRNA) Market Forecast, By End-use 11.16.1. Biotechnology and Pharmaceutical Companies 11.16.2. Academic & Government Research Institutes 11.16.3. Others 11.17. Canada MicroRNA (miRNA) Market Forecast, By Application 11.17.1. Cancer 11.17.2. Infectious Diseases 11.17.3. Immunological Disorder 11.17.4. Cardiovascular Disease 11.17.5. Neurological Disease 11.17.6. Others 11.18. North America MicroRNA (miRNA) Market Attractiveness Analysis 11.18.1. By Research Tools 11.18.2. By End-use 11.18.3. By Application 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe MicroRNA (miRNA) Market Analysis 12.1. Key Findings 12.2. Europe MicroRNA (miRNA) Market Overview 12.3. Europe MicroRNA (miRNA) Market Value Share Analysis, By Research Tools 12.4. Europe MicroRNA (miRNA) Market Forecast, By Research Tools 12.4.1. Services 12.4.1.1. Sample collection 12.4.1.1.1. Whole Blood 12.4.1.1.2. Serum 12.4.1.1.3. Plasma 12.4.1.2. miRNA cDNA Synthesis 12.4.1.3. Profiling & Purification 12.4.1.4. Detection 12.4.1.5. Functional Studies 12.4.1.5.1. NGS 12.4.1.5.2. Microarray 12.4.1.5.3. Real Time PCR 12.4.1.5.4. Others 12.4.2. Products 12.4.2.1. Instruments 12.4.2.2. Consumables 12.4.2.3. Isolation & Purification 12.4.2.4. Quantification & Detection 12.4.2.5. Functional Analysis 12.4.2.6. Others 12.5. Europe MicroRNA (miRNA) Market Value Share Analysis, By End-use 12.6. Europe MicroRNA (miRNA) Market Forecast, By End-use 12.6.1. Biotechnology and Pharmaceutical Companies 12.6.2. Academic & Government Research Institutes 12.6.3. Others 12.7. Europe MicroRNA (miRNA) Market Value Share Analysis, By Application 12.8. Europe MicroRNA (miRNA) Market Forecast, By Application 12.8.1. Cancer 12.8.2. Infectious Diseases 12.8.3. Immunological Disorder 12.8.4. Cardiovascular Disease 12.8.5. Neurological Disease 12.8.6. Others 12.9. Europe MicroRNA (miRNA) Market Value Share Analysis, by Country 12.10. Europe MicroRNA (miRNA) Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Norway 12.10.7. Russia 12.11. Europe MicroRNA (miRNA) Market Analysis, by Country 12.12. Germany MicroRNA (miRNA) Market Forecast, By Research Tools 12.12.1. Services 12.12.1.1. Sample collection 12.12.1.1.1. Whole Blood 12.12.1.1.2. Serum 12.12.1.1.3. Plasma 12.12.1.2. miRNA cDNA Synthesis 12.12.1.3. Profiling & Purification 12.12.1.4. Detection 12.12.1.5. Functional Studies 12.12.1.5.1. NGS 12.12.1.5.2. Microarray 12.12.1.5.3. Real Time PCR 12.12.1.5.4. Others 12.12.2. Products 12.12.2.1. Instruments 12.12.2.2. Consumables 12.12.2.3. Isolation & Purification 12.12.2.4. Quantification & Detection 12.12.2.5. Functional Analysis 12.12.2.6. Others 12.13. Germany MicroRNA (miRNA) Market Forecast, By End-use 12.13.1. Biotechnology and Pharmaceutical Companies 12.13.2. Academic & Government Research Institutes 12.13.3. Others 12.14. Germany MicroRNA (miRNA) Market Forecast, By Application 12.14.1. Cancer 12.14.2. Infectious Diseases 12.14.3. Immunological Disorder 12.14.4. Cardiovascular Disease 12.14.5. Neurological Disease 12.14.6. Others 12.15. U.K. MicroRNA (miRNA) Market Forecast, By Research Tools 12.15.1. Services 12.15.1.1. Sample collection 12.15.1.1.1. Whole Blood 12.15.1.1.2. Serum 12.15.1.1.3. Plasma 12.15.1.2. miRNA cDNA Synthesis 12.15.1.3. Profiling & Purification 12.15.1.4. Detection 12.15.1.5. Functional Studies 12.15.1.5.1. NGS 12.15.1.5.2. Microarray 12.15.1.5.3. Real Time PCR 12.15.1.5.4. Others 12.15.2. Products 12.15.2.1. Instruments 12.15.2.2. Consumables 12.15.2.3. Isolation & Purification 12.15.2.4. Quantification & Detection 12.15.2.5. Functional Analysis 12.15.2.6. Others 12.16. U.K. MicroRNA (miRNA) Market Forecast, By End-use 12.16.1. Biotechnology and Pharmaceutical Companies 12.16.2. Academic & Government Research Institutes 12.16.3. Others 12.17. U.K. MicroRNA (miRNA) Market Forecast, By Application 12.17.1. Cancer 12.17.2. Infectious Diseases 12.17.3. Immunological Disorder 12.17.4. Cardiovascular Disease 12.17.5. Neurological Disease 12.17.6. Others 12.18. France MicroRNA (miRNA) Market Forecast, By Research Tools 12.18.1. Services 12.18.1.1. Sample collection 12.18.1.1.1. Whole Blood 12.18.1.1.2. Serum 12.18.1.1.3. Plasma 12.18.1.2. miRNA cDNA Synthesis 12.18.1.3. Profiling & Purification 12.18.1.4. Detection 12.18.1.5. Functional Studies 12.18.1.5.1. NGS 12.18.1.5.2. Microarray 12.18.1.5.3. Real Time PCR 12.18.1.5.4. Others 12.18.2. Products 12.18.2.1. Instruments 12.18.2.2. Consumables 12.18.2.3. Isolation & Purification 12.18.2.4. Quantification & Detection 12.18.2.5. Functional Analysis 12.18.2.6. Others 12.19. France MicroRNA (miRNA) Market Forecast, By End-use 12.19.1. Biotechnology and Pharmaceutical Companies 12.19.2. Academic & Government Research Institutes 12.19.3. Others 12.20. France MicroRNA (miRNA) Market Forecast, By Application 12.20.1. Cancer 12.20.2. Infectious Diseases 12.20.3. Immunological Disorder 12.20.4. Cardiovascular Disease 12.20.5. Neurological Disease 12.20.6. Others 12.21. Italy MicroRNA (miRNA) Market Forecast, By Research Tools 12.21.1. Services 12.21.1.1. Sample collection 12.21.1.1.1. Whole Blood 12.21.1.1.2. Serum 12.21.1.1.3. Plasma 12.21.1.2. miRNA cDNA Synthesis 12.21.1.3. Profiling & Purification 12.21.1.4. Detection 12.21.1.5. Functional Studies 12.21.1.5.1. NGS 12.21.1.5.2. Microarray 12.21.1.5.3. Real Time PCR 12.21.1.5.4. Others 12.21.2. Products 12.21.2.1. Instruments 12.21.2.2. Consumables 12.21.2.3. Isolation & Purification 12.21.2.4. Quantification & Detection 12.21.2.5. Functional Analysis 12.21.2.6. Others 12.22. Italy MicroRNA (miRNA) Market Forecast, By End-use 12.22.1. Biotechnology and Pharmaceutical Companies 12.22.2. Academic & Government Research Institutes 12.22.3. Others 12.23. Italy MicroRNA (miRNA) Market Forecast, By Application 12.23.1. Cancer 12.23.2. Infectious Diseases 12.23.3. Immunological Disorder 12.23.4. Cardiovascular Disease 12.23.5. Neurological Disease 12.23.6. Others 12.24. Spain MicroRNA (miRNA) Market Forecast, By Research Tools 12.24.1. Services 12.24.1.1. Sample collection 12.24.1.1.1. Whole Blood 12.24.1.1.2. Serum 12.24.1.1.3. Plasma 12.24.1.2. miRNA cDNA Synthesis 12.24.1.3. Profiling & Purification 12.24.1.4. Detection 12.24.1.5. Functional Studies 12.24.1.5.1. NGS 12.24.1.5.2. Microarray 12.24.1.5.3. Real Time PCR 12.24.1.5.4. Others 12.24.2. Products 12.24.2.1. Instruments 12.24.2.2. Consumables 12.24.2.3. Isolation & Purification 12.24.2.4. Quantification & Detection 12.24.2.5. Functional Analysis 12.24.2.6. Others 12.25. Spain MicroRNA (miRNA) Market Forecast, By End-use 12.25.1. Biotechnology and Pharmaceutical Companies 12.25.2. Academic & Government Research Institutes 12.25.3. Others 12.26. Spain MicroRNA (miRNA) Market Forecast, By Application 12.26.1. Cancer 12.26.2. Infectious Diseases 12.26.3. Immunological Disorder 12.26.4. Cardiovascular Disease 12.26.5. Neurological Disease 12.26.6. Others 12.27. Norway MicroRNA (miRNA) Market Forecast, By Research Tools 12.27.1. Services 12.27.1.1. Sample collection 12.27.1.1.1. Whole Blood 12.27.1.1.2. Serum 12.27.1.1.3. Plasma 12.27.1.2. miRNA cDNA Synthesis 12.27.1.3. Profiling & Purification 12.27.1.4. Detection 12.27.1.5. Functional Studies 12.27.1.5.1. NGS 12.27.1.5.2. Microarray 12.27.1.5.3. Real Time PCR 12.27.1.5.4. Others 12.27.2. Products 12.27.2.1. Instruments 12.27.2.2. Consumables 12.27.2.3. Isolation & Purification 12.27.2.4. Quantification & Detection 12.27.2.5. Functional Analysis 12.27.2.6. Others 12.28. Norway MicroRNA (miRNA) Market Forecast, By End-use 12.28.1. Biotechnology and Pharmaceutical Companies 12.28.2. Academic & Government Research Institutes 12.28.3. Others 12.29. Norway MicroRNA (miRNA) Market Forecast, By Application 12.29.1. Cancer 12.29.2. Infectious Diseases 12.29.3. Immunological Disorder 12.29.4. Cardiovascular Disease 12.29.5. Neurological Disease 12.29.6. Others 12.30. Russia MicroRNA (miRNA) Market Forecast, By Research Tools 12.30.1. Services 12.30.1.1. Sample collection 12.30.1.1.1. Whole Blood 12.30.1.1.2. Serum 12.30.1.1.3. Plasma 12.30.1.2. miRNA cDNA Synthesis 12.30.1.3. Profiling & Purification 12.30.1.4. Detection 12.30.1.5. Functional Studies 12.30.1.5.1. NGS 12.30.1.5.2. Microarray 12.30.1.5.3. Real Time PCR 12.30.1.5.4. Others 12.30.2. Products 12.30.2.1. Instruments 12.30.2.2. Consumables 12.30.2.3. Isolation & Purification 12.30.2.4. Quantification & Detection 12.30.2.5. Functional Analysis 12.30.2.6. Others 12.31. Russia MicroRNA (miRNA) Market Forecast, By End-use 12.31.1. Biotechnology and Pharmaceutical Companies 12.31.2. Academic & Government Research Institutes 12.31.3. Others 12.32. Russia MicroRNA (miRNA) Market Forecast, By Application 12.32.1. Cancer 12.32.2. Infectious Diseases 12.32.3. Immunological Disorder 12.32.4. Cardiovascular Disease 12.32.5. Neurological Disease 12.32.6. Others 12.33. Europe MicroRNA (miRNA) Market Attractiveness Analysis 12.33.1. By Research Tools 12.33.2. By End-use 12.33.3. By Application 12.34. PEST Analysis 12.35. Key Trends 12.36. Key Developments 13. Asia Pacific MicroRNA (miRNA) Market Analysis 13.1. Key Findings 13.2. Asia Pacific MicroRNA (miRNA) Market Overview 13.3. Asia Pacific MicroRNA (miRNA) Market Value Share Analysis, By Research Tools 13.4. Asia Pacific MicroRNA (miRNA) Market Forecast, By Research Tools 13.4.1. Services 13.4.1.1. Sample collection 13.4.1.1.1. Whole Blood 13.4.1.1.2. Serum 13.4.1.1.3. Plasma 13.4.1.2. miRNA cDNA Synthesis 13.4.1.3. Profiling & Purification 13.4.1.4. Detection 13.4.1.5. Functional Studies 13.4.1.5.1. NGS 13.4.1.5.2. Microarray 13.4.1.5.3. Real Time PCR 13.4.1.5.4. Others 13.4.2. Products 13.4.2.1. Instruments 13.4.2.2. Consumables 13.4.2.3. Isolation & Purification 13.4.2.4. Quantification & Detection 13.4.2.5. Functional Analysis 13.4.2.6. Others 13.5. Asia Pacific MicroRNA (miRNA) Market Value Share Analysis, By End-use 13.6. Asia Pacific MicroRNA (miRNA) Market Forecast, By End-use 13.6.1. Biotechnology and Pharmaceutical Companies 13.6.2. Academic & Government Research Institutes 13.6.3. Others 13.7. Asia Pacific MicroRNA (miRNA) Market Value Share Analysis, By Application 13.8. Asia Pacific MicroRNA (miRNA) Market Forecast, By Application 13.8.1. Cancer 13.8.2. Infectious Diseases 13.8.3. Immunological Disorder 13.8.4. Cardiovascular Disease 13.8.5. Neurological Disease 13.8.6. Others 13.9. Asia Pacific MicroRNA (miRNA) Market Value Share Analysis, by Country 13.10. Asia Pacific MicroRNA (miRNA) Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. South Korea 13.10.5. Australia 13.10.6. Malaysia 13.10.7. Indonesia 13.11. Asia Pacific MicroRNA (miRNA) Market Analysis, by Country 13.12. China MicroRNA (miRNA) Market Forecast, By Research Tools 13.12.1. Services 13.12.1.1. Sample collection 13.12.1.1.1. Whole Blood 13.12.1.1.2. Serum 13.12.1.1.3. Plasma 13.12.1.2. miRNA cDNA Synthesis 13.12.1.3. Profiling & Purification 13.12.1.4. Detection 13.12.1.5. Functional Studies 13.12.1.5.1. NGS 13.12.1.5.2. Microarray 13.12.1.5.3. Real Time PCR 13.12.1.5.4. Others 13.12.2. Products 13.12.2.1. Instruments 13.12.2.2. Consumables 13.12.2.3. Isolation & Purification 13.12.2.4. Quantification & Detection 13.12.2.5. Functional Analysis 13.12.2.6. Others 13.13. China MicroRNA (miRNA) Market Forecast, By End-use 13.13.1. Biotechnology and Pharmaceutical Companies 13.13.2. Academic & Government Research Institutes 13.13.3. Others 13.14. China MicroRNA (miRNA) Market Forecast, By Application 13.14.1. Cancer 13.14.2. Infectious Diseases 13.14.3. Immunological Disorder 13.14.4. Cardiovascular Disease 13.14.5. Neurological Disease 13.14.6. Others 13.15. India MicroRNA (miRNA) Market Forecast, By Research Tools 13.15.1. Services 13.15.1.1. Sample collection 13.15.1.1.1. Whole Blood 13.15.1.1.2. Serum 13.15.1.1.3. Plasma 13.15.1.2. miRNA cDNA Synthesis 13.15.1.3. Profiling & Purification 13.15.1.4. Detection 13.15.1.5. Functional Studies 13.15.1.5.1. NGS 13.15.1.5.2. Microarray 13.15.1.5.3. Real Time PCR 13.15.1.5.4. Others 13.15.2. Products 13.15.2.1. Instruments 13.15.2.2. Consumables 13.15.2.3. Isolation & Purification 13.15.2.4. Quantification & Detection 13.15.2.5. Functional Analysis 13.15.2.6. Others 13.16. India MicroRNA (miRNA) Market Forecast, By End-use 13.16.1. Biotechnology and Pharmaceutical Companies 13.16.2. Academic & Government Research Institutes 13.16.3. Others 13.17. India MicroRNA (miRNA) Market Forecast, By Application 13.17.1. Cancer 13.17.2. Infectious Diseases 13.17.3. Immunological Disorder 13.17.4. Cardiovascular Disease 13.17.5. Neurological Disease 13.17.6. Others 13.18. Japan MicroRNA (miRNA) Market Forecast, By Research Tools 13.18.1. Services 13.18.1.1. Sample collection 13.18.1.1.1. Whole Blood 13.18.1.1.2. Serum 13.18.1.1.3. Plasma 13.18.1.2. miRNA cDNA Synthesis 13.18.1.3. Profiling & Purification 13.18.1.4. Detection 13.18.1.5. Functional Studies 13.18.1.5.1. NGS 13.18.1.5.2. Microarray 13.18.1.5.3. Real Time PCR 13.18.1.5.4. Others 13.18.2. Products 13.18.2.1. Instruments 13.18.2.2. Consumables 13.18.2.3. Isolation & Purification 13.18.2.4. Quantification & Detection 13.18.2.5. Functional Analysis 13.18.2.6. Others 13.19. Japan MicroRNA (miRNA) Market Forecast, By End-use 13.19.1. Biotechnology and Pharmaceutical Companies 13.19.2. Academic & Government Research Institutes 13.19.3. Others 13.20. Japan MicroRNA (miRNA) Market Forecast, By Application 13.20.1. Cancer 13.20.2. Infectious Diseases 13.20.3. Immunological Disorder 13.20.4. Cardiovascular Disease 13.20.5. Neurological Disease 13.20.6. Others 13.21. South Korea MicroRNA (miRNA) Market Forecast, By Research Tools 13.21.1. Services 13.21.1.1. Sample collection 13.21.1.1.1. Whole Blood 13.21.1.1.2. Serum 13.21.1.1.3. Plasma 13.21.1.2. miRNA cDNA Synthesis 13.21.1.3. Profiling & Purification 13.21.1.4. Detection 13.21.1.5. Functional Studies 13.21.1.5.1. NGS 13.21.1.5.2. Microarray 13.21.1.5.3. Real Time PCR 13.21.1.5.4. Others 13.21.2. Products 13.21.2.1. Instruments 13.21.2.2. Consumables 13.21.2.3. Isolation & Purification 13.21.2.4. Quantification & Detection 13.21.2.5. Functional Analysis 13.21.2.6. Others 13.22. South Korea MicroRNA (miRNA) Market Forecast, By End-use 13.22.1. Biotechnology and Pharmaceutical Companies 13.22.2. Academic & Government Research Institutes 13.22.3. Others 13.23. South Korea MicroRNA (miRNA) Market Forecast, By Application 13.23.1. Cancer 13.23.2. Infectious Diseases 13.23.3. Immunological Disorder 13.23.4. Cardiovascular Disease 13.23.5. Neurological Disease 13.23.6. Others 13.24. Australia MicroRNA (miRNA) Market Forecast, By Research Tools 13.24.1. Services 13.24.1.1. Sample collection 13.24.1.1.1. Whole Blood 13.24.1.1.2. Serum 13.24.1.1.3. Plasma 13.24.1.2. miRNA cDNA Synthesis 13.24.1.3. Profiling & Purification 13.24.1.4. Detection 13.24.1.5. Functional Studies 13.24.1.5.1. NGS 13.24.1.5.2. Microarray 13.24.1.5.3. Real Time PCR 13.24.1.5.4. Others 13.24.2. Products 13.24.2.1. Instruments 13.24.2.2. Consumables 13.24.2.3. Isolation & Purification 13.24.2.4. Quantification & Detection 13.24.2.5. Functional Analysis 13.24.2.6. Others 13.25. Australia MicroRNA (miRNA) Market Forecast, By End-use 13.25.1. Biotechnology and Pharmaceutical Companies 13.25.2. Academic & Government Research Institutes 13.25.3. Others 13.26. Australia MicroRNA (miRNA) Market Forecast, By Application 13.26.1. Cancer 13.26.2. Infectious Diseases 13.26.3. Immunological Disorder 13.26.4. Cardiovascular Disease 13.26.5. Neurological Disease 13.26.6. Others 13.27. Malaysia MicroRNA (miRNA) Market Forecast, By Research Tools 13.27.1. Services 13.27.1.1. Sample collection 13.27.1.1.1. Whole Blood 13.27.1.1.2. Serum 13.27.1.1.3. Plasma 13.27.1.2. miRNA cDNA Synthesis 13.27.1.3. Profiling & Purification 13.27.1.4. Detection 13.27.1.5. Functional Studies 13.27.1.5.1. NGS 13.27.1.5.2. Microarray 13.27.1.5.3. Real Time PCR 13.27.1.5.4. Others 13.27.2. Products 13.27.2.1. Instruments 13.27.2.2. Consumables 13.27.2.3. Isolation & Purification 13.27.2.4. Quantification & Detection 13.27.2.5. Functional Analysis 13.27.2.6. Others 13.28. Malaysia MicroRNA (miRNA) Market Forecast, By End-use 13.28.1. Biotechnology and Pharmaceutical Companies 13.28.2. Academic & Government Research Institutes 13.28.3. Others 13.29. Malaysia MicroRNA (miRNA) Market Forecast, By Application 13.29.1. Cancer 13.29.2. Infectious Diseases 13.29.3. Immunological Disorder 13.29.4. Cardiovascular Disease 13.29.5. Neurological Disease 13.29.6. Others 13.30. Indonesia MicroRNA (miRNA) Market Forecast, By Research Tools 13.30.1. Services 13.30.1.1. Sample collection 13.30.1.1.1. Whole Blood 13.30.1.1.2. Serum 13.30.1.1.3. Plasma 13.30.1.2. miRNA cDNA Synthesis 13.30.1.3. Profiling & Purification 13.30.1.4. Detection 13.30.1.5. Functional Studies 13.30.1.5.1. NGS 13.30.1.5.2. Microarray 13.30.1.5.3. Real Time PCR 13.30.1.5.4. Others 13.30.2. Products 13.30.2.1. Instruments 13.30.2.2. Consumables 13.30.2.3. Isolation & Purification 13.30.2.4. Quantification & Detection 13.30.2.5. Functional Analysis 13.30.2.6. Others 13.31. Indonesia MicroRNA (miRNA) Market Forecast, By End-use 13.31.1. Biotechnology and Pharmaceutical Companies 13.31.2. Academic & Government Research Institutes 13.31.3. Others 13.32. Indonesia MicroRNA (miRNA) Market Forecast, By Application 13.32.1. Cancer 13.32.2. Infectious Diseases 13.32.3. Immunological Disorder 13.32.4. Cardiovascular Disease 13.32.5. Neurological Disease 13.32.6. Others 13.33. Vietnam MicroRNA (miRNA) Market Forecast, By Research Tools 13.33.1. Services 13.33.1.1. Sample collection 13.33.1.1.1. Whole Blood 13.33.1.1.2. Serum 13.33.1.1.3. Plasma 13.33.1.2. miRNA cDNA Synthesis 13.33.1.3. Profiling & Purification 13.33.1.4. Detection 13.33.1.5. Functional Studies 13.33.1.5.1. NGS 13.33.1.5.2. Microarray 13.33.1.5.3. Real Time PCR 13.33.1.5.4. Others 13.33.2. Products 13.33.2.1. Instruments 13.33.2.2. Consumables 13.33.2.3. Isolation & Purification 13.33.2.4. Quantification & Detection 13.33.2.5. Functional Analysis 13.33.2.6. Others 13.34. Vietnam MicroRNA (miRNA) Market Forecast, By End-use 13.34.1. Biotechnology and Pharmaceutical Companies 13.34.2. Academic & Government Research Institutes 13.34.3. Others 13.35. Vietnam MicroRNA (miRNA) Market Forecast, By Application 13.35.1. Cancer 13.35.2. Infectious Diseases 13.35.3. Immunological Disorder 13.35.4. Cardiovascular Disease 13.35.5. Neurological Disease 13.35.6. Others 13.36. Asia Pacific MicroRNA (miRNA) Market Attractiveness Analysis 13.36.1. By Research Tools 13.36.2. By End-use 13.36.3. By Application 13.37. PEST Analysis 13.38. Key Trends 13.39. Key Developments 14. Middle East & Africa MicroRNA (miRNA) Market Analysis 14.1. Key Findings 14.2. Middle East & Africa MicroRNA (miRNA) Market Overview 14.3. Middle East & Africa MicroRNA (miRNA) Market Value Share Analysis, By Research Tools 14.4. Middle East & Africa MicroRNA (miRNA) Market Forecast, By Research Tools 14.4.1. Services 14.4.1.1. Sample collection 14.4.1.1.1. Whole Blood 14.4.1.1.2. Serum 14.4.1.1.3. Plasma 14.4.1.2. miRNA cDNA Synthesis 14.4.1.3. Profiling & Purification 14.4.1.4. Detection 14.4.1.5. Functional Studies 14.4.1.5.1. NGS 14.4.1.5.2. Microarray 14.4.1.5.3. Real Time PCR 14.4.1.5.4. Others 14.4.2. Products 14.4.2.1. Instruments 14.4.2.2. Consumables 14.4.2.3. Isolation & Purification 14.4.2.4. Quantification & Detection 14.4.2.5. Functional Analysis 14.4.2.6. Others 14.5. Middle East & Africa MicroRNA (miRNA) Market Value Share Analysis, By End-use 14.6. Middle East & Africa MicroRNA (miRNA) Market Forecast, By End-use 14.6.1. Biotechnology and Pharmaceutical Companies 14.6.2. Academic & Government Research Institutes 14.6.3. Others 14.7. Middle East & Africa MicroRNA (miRNA) Market Value Share Analysis, By Application 14.8. Middle East & Africa MicroRNA (miRNA) Market Forecast, By Application 14.8.1. Cancer 14.8.2. Infectious Diseases 14.8.3. Immunological Disorder 14.8.4. Cardiovascular Disease 14.8.5. Neurological Disease 14.8.6. Others 14.9. Middle East & Africa MicroRNA (miRNA) Market Value Share Analysis, by Country 14.10. Middle East & Africa MicroRNA (miRNA) Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Nigeria 14.10.4. Egypt 14.11. Middle East & Africa MicroRNA (miRNA) Market Analysis, by Country 14.12. GCC MicroRNA (miRNA) Market Forecast, By Research Tools 14.12.1. Services 14.12.1.1. Sample collection 14.12.1.1.1. Whole Blood 14.12.1.1.2. Serum 14.12.1.1.3. Plasma 14.12.1.2. miRNA cDNA Synthesis 14.12.1.3. Profiling & Purification 14.12.1.4. Detection 14.12.1.5. Functional Studies 14.12.1.5.1. NGS 14.12.1.5.2. Microarray 14.12.1.5.3. Real Time PCR 14.12.1.5.4. Others 14.12.2. Products 14.12.2.1. Instruments 14.12.2.2. Consumables 14.12.2.3. Isolation & Purification 14.12.2.4. Quantification & Detection 14.12.2.5. Functional Analysis 14.12.2.6. Others 14.13. GCC MicroRNA (miRNA) Market Forecast, By End-use 14.13.1. Biotechnology and Pharmaceutical Companies 14.13.2. Academic & Government Research Institutes 14.13.3. Others 14.14. GCC MicroRNA (miRNA) Market Forecast, By Application 14.14.1. Cancer 14.14.2. Infectious Diseases 14.14.3. Immunological Disorder 14.14.4. Cardiovascular Disease 14.14.5. Neurological Disease 14.14.6. Others 14.15. South Africa MicroRNA (miRNA) Market Forecast, By Research Tools 14.15.1. Services 14.15.1.1. Sample collection 14.15.1.1.1. Whole Blood 14.15.1.1.2. Serum 14.15.1.1.3. Plasma 14.15.1.2. miRNA cDNA Synthesis 14.15.1.3. Profiling & Purification 14.15.1.4. Detection 14.15.1.5. Functional Studies 14.15.1.5.1. NGS 14.15.1.5.2. Microarray 14.15.1.5.3. Real Time PCR 14.15.1.5.4. Others 14.15.2. Products 14.15.2.1. Instruments 14.15.2.2. Consumables 14.15.2.3. Isolation & Purification 14.15.2.4. Quantification & Detection 14.15.2.5. Functional Analysis 14.15.2.6. Others 14.16. South Africa MicroRNA (miRNA) Market Forecast, By End-use 14.16.1. Biotechnology and Pharmaceutical Companies 14.16.2. Academic & Government Research Institutes 14.16.3. Others 14.17. South Africa MicroRNA (miRNA) Market Forecast, By Application 14.17.1. Cancer 14.17.2. Infectious Diseases 14.17.3. Immunological Disorder 14.17.4. Cardiovascular Disease 14.17.5. Neurological Disease 14.17.6. Others 14.18. Nigeria MicroRNA (miRNA) Market Forecast, By Research Tools 14.18.1. Services 14.18.1.1. Sample collection 14.18.1.1.1. Whole Blood 14.18.1.1.2. Serum 14.18.1.1.3. Plasma 14.18.1.2. miRNA cDNA Synthesis 14.18.1.3. Profiling & Purification 14.18.1.4. Detection 14.18.1.5. Functional Studies 14.18.1.5.1. NGS 14.18.1.5.2. Microarray 14.18.1.5.3. Real Time PCR 14.18.1.5.4. Others 14.18.2. Products 14.18.2.1. Instruments 14.18.2.2. Consumables 14.18.2.3. Isolation & Purification 14.18.2.4. Quantification & Detection 14.18.2.5. Functional Analysis 14.18.2.6. Others 14.19. Nigeria MicroRNA (miRNA) Market Forecast, By End-use 14.19.1. Biotechnology and Pharmaceutical Companies 14.19.2. Academic & Government Research Institutes 14.19.3. Others 14.20. Nigeria MicroRNA (miRNA) Market Forecast, By Application 14.20.1. Cancer 14.20.2. Infectious Diseases 14.20.3. Immunological Disorder 14.20.4. Cardiovascular Disease 14.20.5. Neurological Disease 14.20.6. Others 14.21. Egypt MicroRNA (miRNA) Market Forecast, By Research Tools 14.21.1. Services 14.21.1.1. Sample collection 14.21.1.1.1. Whole Blood 14.21.1.1.2. Serum 14.21.1.1.3. Plasma 14.21.1.2. miRNA cDNA Synthesis 14.21.1.3. Profiling & Purification 14.21.1.4. Detection 14.21.1.5. Functional Studies 14.21.1.5.1. NGS 14.21.1.5.2. Microarray 14.21.1.5.3. Real Time PCR 14.21.1.5.4. Others 14.21.2. Products 14.21.2.1. Instruments 14.21.2.2. Consumables 14.21.2.3. Isolation & Purification 14.21.2.4. Quantification & Detection 14.21.2.5. Functional Analysis 14.21.2.6. Others 14.22. Egypt MicroRNA (miRNA) Market Forecast, By End-use 14.22.1. Biotechnology and Pharmaceutical Companies 14.22.2. Academic & Government Research Institutes 14.22.3. Others 14.23. Egypt MicroRNA (miRNA) Market Forecast, By Application 14.23.1. Cancer 14.23.2. Infectious Diseases 14.23.3. Immunological Disorder 14.23.4. Cardiovascular Disease 14.23.5. Neurological Disease 14.23.6. Others 14.24. Middle East & Africa MicroRNA (miRNA) Market Attractiveness Analysis 14.24.1. By Research Tools 14.24.2. By End-use 14.24.3. By Application 14.25. PEST Analysis 14.26. Key Trends 14.27. Key Developments 15. South America MicroRNA (miRNA) Market Analysis 15.1. Key Findings 15.2. South America MicroRNA (miRNA) Market Overview 15.3. South America MicroRNA (miRNA) Market Value Share Analysis, By Research Tools 15.4. South America MicroRNA (miRNA) Market Forecast, By Research Tools 15.4.1. Services 15.4.1.1. Sample collection 15.4.1.1.1. Whole Blood 15.4.1.1.2. Serum 15.4.1.1.3. Plasma 15.4.1.2. miRNA cDNA Synthesis 15.4.1.3. Profiling & Purification 15.4.1.4. Detection 15.4.1.5. Functional Studies 15.4.1.5.1. NGS 15.4.1.5.2. Microarray 15.4.1.5.3. Real Time PCR 15.4.1.5.4. Others 15.4.2. Products 15.4.2.1. Instruments 15.4.2.2. Consumables 15.4.2.3. Isolation & Purification 15.4.2.4. Quantification & Detection 15.4.2.5. Functional Analysis 15.4.2.6. Others 15.5. South America MicroRNA (miRNA) Market Value Share Analysis, By End-use 15.6. South America MicroRNA (miRNA) Market Forecast, By End-use 15.6.1. Biotechnology and Pharmaceutical Companies 15.6.2. Academic & Government Research Institutes 15.6.3. Others 15.7. South America MicroRNA (miRNA) Market Value Share Analysis, By Application 15.8. South America MicroRNA (miRNA) Market Forecast, By Application 15.8.1. Cancer 15.8.2. Infectious Diseases 15.8.3. Immunological Disorder 15.8.4. Cardiovascular Disease 15.8.5. Neurological Disease 15.8.6. Others 15.9. South America MicroRNA (miRNA) Market Value Share Analysis, by Country 15.10. South America MicroRNA (miRNA) Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Argentina 15.11. South America MicroRNA (miRNA) Market Analysis, by Country 15.12. Brazil MicroRNA (miRNA) Market Forecast, By Research Tools 15.12.1. Services 15.12.1.1. Sample collection 15.12.1.1.1. Whole Blood 15.12.1.1.2. Serum 15.12.1.1.3. Plasma 15.12.1.2. miRNA cDNA Synthesis 15.12.1.3. Profiling & Purification 15.12.1.4. Detection 15.12.1.5. Functional Studies 15.12.1.5.1. NGS 15.12.1.5.2. Microarray 15.12.1.5.3. Real Time PCR 15.12.1.5.4. Others 15.12.2. Products 15.12.2.1. Instruments 15.12.2.2. Consumables 15.12.2.3. Isolation & Purification 15.12.2.4. Quantification & Detection 15.12.2.5. Functional Analysis 15.12.2.6. Others 15.13. Brazil MicroRNA (miRNA) Market Forecast, By End-use 15.13.1. Biotechnology and Pharmaceutical Companies 15.13.2. Academic & Government Research Institutes 15.13.3. Others 15.14. Brazil MicroRNA (miRNA) Market Forecast, By Application 15.14.1. Cancer 15.14.2. Infectious Diseases 15.14.3. Immunological Disorder 15.14.4. Cardiovascular Disease 15.14.5. Neurological Disease 15.14.6. Others 15.15. Mexico MicroRNA (miRNA) Market Forecast, By Research Tools 15.15.1. Services 15.15.1.1. Sample collection 15.15.1.1.1. Whole Blood 15.15.1.1.2. Serum 15.15.1.1.3. Plasma 15.15.1.2. miRNA cDNA Synthesis 15.15.1.3. Profiling & Purification 15.15.1.4. Detection 15.15.1.5. Functional Studies 15.15.1.5.1. NGS 15.15.1.5.2. Microarray 15.15.1.5.3. Real Time PCR 15.15.1.5.4. Others 15.15.2. Products 15.15.2.1. Instruments 15.15.2.2. Consumables 15.15.2.3. Isolation & Purification 15.15.2.4. Quantification & Detection 15.15.2.5. Functional Analysis 15.15.2.6. Others 15.16. Mexico MicroRNA (miRNA) Market Forecast, By End-use 15.16.1. Biotechnology and Pharmaceutical Companies 15.16.2. Academic & Government Research Institutes 15.16.3. Others 15.17. Mexico MicroRNA (miRNA) Market Forecast, By Application 15.17.1. Cancer 15.17.2. Infectious Diseases 15.17.3. Immunological Disorder 15.17.4. Cardiovascular Disease 15.17.5. Neurological Disease 15.17.6. Others 15.18. Argentina MicroRNA (miRNA) Market Forecast, By Research Tools 15.18.1. Services 15.18.1.1. Sample collection 15.18.1.1.1. Whole Blood 15.18.1.1.2. Serum 15.18.1.1.3. Plasma 15.18.1.2. miRNA cDNA Synthesis 15.18.1.3. Profiling & Purification 15.18.1.4. Detection 15.18.1.5. Functional Studies 15.18.1.5.1. NGS 15.18.1.5.2. Microarray 15.18.1.5.3. Real Time PCR 15.18.1.5.4. Others 15.18.2. Products 15.18.2.1. Instruments 15.18.2.2. Consumables 15.18.2.3. Isolation & Purification 15.18.2.4. Quantification & Detection 15.18.2.5. Functional Analysis 15.18.2.6. Others 15.19. Argentina MicroRNA (miRNA) Market Forecast, By End-use 15.19.1. Biotechnology and Pharmaceutical Companies 15.19.2. Academic & Government Research Institutes 15.19.3. Others 15.20. Argentina MicroRNA (miRNA) Market Forecast, By Application 15.20.1. Cancer 15.20.2. Infectious Diseases 15.20.3. Immunological Disorder 15.20.4. Cardiovascular Disease 15.20.5. Neurological Disease 15.20.6. Others 15.21. South America MicroRNA (miRNA) Market Attractiveness Analysis 15.21.1. By Research Tools 15.21.2. By End-use 15.21.3. By Application 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Illumina, Inc. 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. F. Hoffmann-La Roche Ltd 16.3.3. Agilent Technologies 16.3.4. Bio-Rad Laboratories Inc. 16.3.5. Sigma Aldrich Corp. 16.3.6. Qiagen N.V 16.3.7. Thermo Fisher Scientific, Inc. 16.3.8. HTG Molecular Diagnostics, Inc. 16.3.9. Bioline GmbH (A Meridian Life Science Company) 16.3.10. Rosetta Genomics Ltd. 16.3.11. Dharmacon, a Horizon Discovery Group Co. 16.3.12. BioVendor — Laboratorní medicína a.s. 16.3.13. Miltenyi Biotec 16.3.14. Kaneka Corporation (Eurogentec) 16.3.15. Abcam Plc 16.3.16. GeneCopoeia, Inc. 16.3.17. Promega Corporation 16.3.18. New England Biolabs, Inc. 16.3.19. NanoString Technologies, Inc. 16.3.20. System Biosciences LLC 16.3.21. Others. 17. Primary Key Insights

About This Report

Report ID 78133
Category Healthcare
Published Date November 2020
Updated Date Feb 2022
Contact Us